2021 crypto to buy Top Knowledge graph

Dongpeng Beverage has set up two new companies in Hainan. According to the enterprise search APP, Hainan Dongpeng Beverage Marketing Co., Ltd. and Hainan Dongpeng Food & Beverage Co., Ltd. were established recently, and their legal representatives are both Liu Meili, with a registered capital of 100 million yuan. Enterprise investigation shows that both of them are wholly owned by Dongpeng Beverage.In the latest centralized purchase of sitagliptin tablets, the price dropped to less than 20 cents per tablet, with a drop of over 90%. The reporter learned at the scene of the tenth batch of drug centralized purchase that more than 30 companies bid for sitagliptin, which is known as the largest variety in this centralized purchase, including Huahai Pharmaceutical, Kelun Pharmaceutical, Zhengda Tianqing, tonghua dongbao, Zhejiang Pharmaceutical, Jiudian Pharmaceutical, Shiyao Ouyi, Chenxin Pharmaceutical and many other companies. Judging from the bidding results, the lowest bid price among enterprises has dropped below 0.2 yuan per piece, which is more than 90% lower than the limit price. Statistics show that in 2023, the sales of this product in the terminals of public medical institutions in China exceeded 2 billion yuan, and the sales of Merck, the original research manufacturer, accounted for more than 90%, so there is a large room for generic drug substitution. The quotation of Meradong in this collection is about 7.37 yuan per piece. (science and technology innovation board Daily)The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)

People's Insurance Company of China: In the first November, the original insurance premium income of the three subsidiaries totaled 646.933 billion yuan. From January 1, 2024 to November 30, 2024, the original insurance premium income obtained through the subsidiaries of China People's Property Insurance Co., Ltd., China People's Life Insurance Co., Ltd. and China People's Health Insurance Co., Ltd. was 496.845 billion yuan, 102.591 billion yuan and 47.497 billion yuan respectively.Schlegel, Governor of the Swiss National Bank: Since the last interest rate decision, the inflation rate has been lower than expected. The development of the Swiss franc is still an important factor.Schlegel, Governor of Swiss National Bank: If monetary policy needs to be further relaxed, interest rate reduction is still the main tool. The Swiss National Bank is still willing to intervene in the foreign exchange market when necessary.

Jichuan Pharmaceutical Co., Ltd. and Dongke Pharmaceutical Co., Ltd., a wholly-owned subsidiary, have recently received the Drug Registration Certificate for Children Faropenem Sodium Granules and Cefezoxime Sodium for Injection approved and issued by National Medical Products Administration.Lu Dongsheng was appointed Deputy Secretary and General Manager of the Party Committee of Shanghai Futures Exchange. The Party Committee of China Securities Regulatory Commission decided that Comrade Lu Dongsheng was appointed Deputy Secretary and General Manager of the Party Committee of Shanghai Futures Exchange. Comrade Wang Fenghai no longer serves as deputy secretary and general manager of the Party Committee of Shanghai Futures Exchange. (website of last issue)The RMB exchange rate is expected to appreciate again at the end of the year. The research team of the Financial Market Department of Agricultural Bank of China said that the market transactions have shown obvious narrative-driven characteristics in recent years. Considering some recent changes, the RMB exchange rate is expected to stabilize and rebound again in the future. First, the pricing of Trump transactions in the international market has come to an end. Second, there has been a major shift in domestic macro policies. Since late September, financial policies such as lowering the RRR, cutting interest rates, supporting the stock market and the real estate market, and fiscal debt measures have boosted market confidence. Third, there has been a favorable change in supply and demand in the domestic foreign exchange market. The end of the year is the traditional peak season for enterprises to settle foreign exchange, and the continuous forward discount will lead to the backlog of foreign exchange settlement, which will further amplify the demand for foreign exchange settlement at the end of the year. Further considering the overall situation of the game between China and the United States, Trump's return not only means the enhancement of external shocks, but also the upgrading of internal policies. The RMB exchange rate will maintain two-way fluctuations next year, and it is no longer a steady profit for enterprises to hold US dollars and postpone foreign exchange settlement. While stabilizing domestic foreign trade and foreign investment, continuing to expand high-level opening-up and expanding domestic demand in an all-round way implies the certainty of economic stabilization and recovery, which is expected to promote the return of short-term securities investment and medium-and long-term direct investment and help the RMB stop falling and rebound.